Vanguard Fiduciary Trust
CAPR icon

Vanguard Fiduciary Trust’s Capricor Therapeutics CAPR Stock Holding History

Vanguard Fiduciary Trust’s Portfolio CAPR Stock Details CAPR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$8.97M Buy
372,539
+52,441
+16% +$1.59M ﹤0.01% 1872
2026
Q1 		$9.73M Buy
+320,098
New +$8.53M ﹤0.01% 1730

Other funds holding CAPR

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BCM
Boxer Capital Management San Diego, California $1.33B AUM 864.5% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Vanguard Fiduciary Trust's CAPR Position: Q2 2026 in Review

Vanguard Fiduciary Trust increased its Capricor Therapeutics (CAPR) stake by 16% in Q2 2026, buying an estimated $1.59M and bringing the position to 372,539 shares worth $8.97M. The position accounts for ﹤0.01% of the portfolio, ranked #1872.

Vanguard Fiduciary Trust first reported a position in CAPR in Q1 2026 and has held it in 2 quarters since. The position peaked at $9.73M in Q1 2026. 169 funds tracked by Wall St. Rank hold CAPR as of Q2 2026.

  • Vanguard Fiduciary Trust held 372,539 shares of Capricor Therapeutics worth $8.97M as of Q2 2026.
  • Vanguard Fiduciary Trust bought 52,441 Capricor Therapeutics shares in Q2 2026, an estimated $1.59M.
  • Capricor Therapeutics made up ﹤0.01% of Vanguard Fiduciary Trust's portfolio in Q2 2026, its #1872 holding.
  • Vanguard Fiduciary Trust first reported a position in Capricor Therapeutics in Q1 2026 and has held it in 2 quarters since.
  • Vanguard Fiduciary Trust's Capricor Therapeutics position peaked at $9.73M in Q1 2026.
  • 169 funds tracked by Wall St. Rank held Capricor Therapeutics as of Q2 2026.

Based on Vanguard Fiduciary Trust's 13F filing for Q2 2026, filed 13 Aug 2026.